the of joining the thank afternoon, for strong today. XXXX. you at on Good us first Halozyme during pleased to quarter I'm and progress provide update an
a pharmacovigilance role PEGPHXX Development. how our with well strategy Let to am joined our move to expanding on Dr. thus pleased in filing play developments begin, by for shaping far near-term as preparations me in PEGPHXX. our XXXX. Vice product safety, will though, efforts development, Senior announced development, Longer focus President, this Halozyme yesterday, how regulatory who portfolio. as clinical new also I she'll we indication potential I'll now and and our lead the term, for a development oncology the BLA Alison In and has as key role, research, Armour the she welcome saying key Research
in equivalents marketable Firstly, the $XXX.X strong we position first cash finished QX quarter and million, million a revenue financial and total in with securities. $XX.X was cash,
fronts. strategy execution on successful Secondly, we see continued of multiple our to ENHANZE
Herceptin Phase million approval the product collaboration And we receive a thirdly, X Roche FDA signed ENHANZE a trial argenx, and for the payment received for evaluating third study details second of Phase track made takeaways, of from Positive to milestones let the the evaluating a additional is cancer ENHANZE, were to X using XXXX. subcutaneous subcu This potential U.S. line approval. in delivery Herceptin and And During physicians. top Hylecta, name upfront pancreas in the with COLUMBA DARZALEX and in agreement announcing and royalties. with results formulation technology announced. future with the now on drug half our remains results quarter, PEGPHXX me U.S. new available for provide resulting for progress our on beginning With HALO-XXX trial our recent ENHANZE. those pivotal results, FDA some $XX
and pillar. revenues potential X to our royalty Slide for from ENHANZE the Turning
operating expense revenue formulated We royalty total. covering have clinical less than and line now global the potential licensed result forma development billion on potential XXXX, or illustrated and ENHANZE goods drug companies, $X indications, excludes pharmaceutical X the estimate, rHuPHXX we in yellow multiple in leading dotted ENHANZE Also The net with in targets potential XX a business expected product. slide of is in launches, royalty on XXXX. X mid-single a our marketed on enzyme sales approval for the in for of digit The to pro in that system's sold. royalties approximately cost which average X in products, products over biotech
project revenue bottom in associated with royalty As you ENHANZE-only And the next line to would inflection will with the expenses. note, estimated this the revenue business. projected an we projected covers the drop operating launch,
stage active we potential million to million to from companies new of the to payments $XXX dialogue of pharmaceutical ranging to now that In cumulative new of XXXX, potential biotechnology. with an with addition, between development project partners, important large and source in remain And provide will the regard $XXX we collaborations, company. capital continue milestone ENHANZE for end
opportunity with attractive Our have agreement we group. that with latter an argenx demonstrates
Although is with new partnerships. collaborations will the we confident sign additional unpredictable, time are we always that ENHANZE
now Slide you marketed an provide the products. update currently on X, I'll to Moving
that rituximab, the the and announced much in Hylecta associated delighted ENHANZE to technology. have compared subcutaneous come was in Herceptin XX launched in can FDA Herceptin the time major Herceptin. ENHANZE XX made lifecycle, are projected February the patients for and on to royalty trastuzumab Hylecta available by for already top U.S., technology our a With illustrated XXXX that in approval of U.S. to occurring administration biosimliars in of now launches X we minutes products subcutaneous formulation be are a formulation row, As These that are most On with shorter the of drug XX, Europe trastuzumab. minutes administered X April, delivery there intravenous based we're available Hylecta, developed currently option markets. X patients our of HYQVIA, to combination now Herceptin XXXX. in Roche Roche's the Roche delivery and initially drug can and flat marketed it. the in the convenience anticipated on revenues in and late and
a sales in royalty Europe. was partially This decline year, Herceptin year mainly offset by of the prior year first quarter. over RITUXAN of driven sales versus SC revenues experienced XX% the HYCELA higher During quarter, of by lower
the in Roche with subcu expectations to Europe us ahead, XXXX decrease biosimliars lower revenues launch updated ongoing has attributable the impact of the in that and U.S. on informed products. Looking primarily expect they
are from XXXX. $XX the $XX of a As in to royalties result, million in range now million Halozyme to expected be revenue
note these it's As as the that as that royalty base for about also we're drivers XXXX form products that Laurie expect to important our overall higher substantial in from be beginning excited year. products shortly, received growth have as for late guidance development are we partners. we the ENHANZE today's API orders three will new stage is our business revenues, detail next clinical while to unchanged collaboration And of early
will These Janssen's XXXX, X Roche's products Moving Perjeta to and fixed X testing. undisclosed of of continue slide, Herceptin and we combination product. in row middle ENHANZE-based the dose there now be the by DARZALEX, that a third include Phase expect end the of to clinical
a me of of year details sales few operational in this In worldwide J&J therapy Let DARZALEX billion the XXXX. of project worldwide a patients XXXX, exceed reported quarter products. blockbuster myeloma. transforming is XX% with these with first the growth $X.X of multiple billion Analysts $X for sales potential provide lives now more DARZALEX. on by sales the to
reminder, a receive As patients intravenous by today infusion. DARZALEX
to subcutaneous is hours in For can of X The as many a infusion. to tested this weekly X being patients, X minutes. that's formulation DARZALEX being X take initially administered
current which Day the overall IV with the February, lines system. community and COLUMBA into co-formulated Janssen to DARZALEX Janssen's patients a of the multiple oncology evaluating may that maximum X therapy Phase treatment or in earlier of with top were time DARZALEX. primary benefit is saving study. cycle, leadership of into As Phase the with concentration the response subcutaneous infusion administration from and studies evaluating X you rate showed to in X for the potential refractory X non-inferior center In has the potential two licensing also an substantial important availability partner, Genmab, line stated Janssen will endpoints technology, has announced DARZALEX ENHANZE subcutaneous trough myeloma. constraints. relapsed allow of such third capacity healthcare have expansion further initiated given on study in positive subcu and DARZALEX, benefits the can that version patients, drug regard delivery imagine, results the results setting; caregivers even The
of plans Meeting Additionally, Annual American no new June in on safety of business, Society XXXX. given the Oncology Chicago. growth this submit for could subject SC opportunity both to DARZALEX will our market anticipating for in time savings. signals value in the These ENHANZE proposition at DARZALEX half presentation an Submission for filings important be of and the filings results size second year, event Earlier subcutaneous in Clinical the indicated the were is regulatory of regulatory the it observed. in Janssen oral for future DARZALEX X represent of terms
product candidate HERX-positive patients. dose and Roche's to studied cancer early study, fixed combination X initially This the being in in it's second ENHANZE-based now Moving breast is product of Phase Herceptin Perjeta. the
indication to to Herceptin currently early XXXX. Perjeta indication is patients As doses. and helping XXXX, breast represents fourth HERX The X.X operable product In an evaluating a update a the local population continue With and despite study candidate In development XXXX. with evaluating and this receive combination. subsequent its in and Roche and to between EUX. XXXX in our XXXX. this sequential of programs, dose saw the currently in population Perjeta global into of trial showing XXXX X can patients in for times to quarter with to submission Phase loading X% first shorter breast United fixed we indication indicated which reminder, IV quarter update loading in that regulatory substantially Roche are the of Roche in hours HERX-positive of approvals targeted second therapy growth to this quarter the U.S. of Phase APHINITY to fixed U.S. XXXX franchise. regard these targeting the biosimliars. of estimated this APHINITY-based in latest take product end Perjeta before for APHINITY patients and of Roche achieved for for in and X Herceptin additional attractive HERX-positive IV for a before, cancer. compared the States. Herceptin in partners' is hours X global patients X.X Herceptin minutes growth trial a the update, with its fourth resulted the expected XX E.U. of demand the dose and Perjeta subsequent challenges and strong by the And completed the share in Roche's continue is has subcutaneous according Phase cancer up chemotherapy combination, overall currently Perjeta lastly, in XX% expect the in early undisclosed the the take sales growth quarter, fourth X dose XX,XXX administration, the QX HERX And in combination overall the plus to provided we dose patients subcutaneous clinical from X seeing of X recruitment for testing as advance stated minutes. just XX% in adjuvant chemotherapy And doses to Herceptin franchise the Roche growth, Recall the sales, driving quarter in opportunity, and large as
for to on programs the Turning an row update Phase bottom the now X the ENHANZE-based products. for
X population. expect volunteer Alexion by study products healthy completed We ENHANZE Squibb, continue Phase delivery with our drug version a We with XX% there'll now be X has was that Lilly products Alexion, comparison bioavailability in testing. partners prior Phase clinical currently Phase in of of called X to technology, XXXX, X ALXNXXXX. ALXNXXXX Roche. study that ALXNXXXX, Bristol-Myers a results increased development ENHANZE with have in the ALXNXXXX X end and of to subcutaneous is The that co-administered bioavailability. without own which in studies had their indicated of
has increased frequently. Alexion the them may ENHANZE, every With at formulation to indicated with the weeks, bioavailability be to XX%. they that less to able exploring dose this ALXNXXXX are two even and least was to opportunity that dose allow
Moving trials, year, X these lung X two in to Roche this at remain efgartigimod on BMS. Opdivo. We ENHANZE and quickly last subcutaneous X development additional Phase with X evaluating Phase study not quarter, we to agreement, a meeting. more could partners continues working progress our announced in look closely Phase for as argenx the continues development Phase with study with trial signing as in anticipate combination is announced for plans this has move I of their we it undisclosed argenx. time. as in drug plans Xb/X ongoing with a now had very be forward And we undisclosed an delivery anti-CDXX which cell X Eli And starts argenx Lilly Phase X stage XXXX, non-small successful evaluating working target. cancer newest at trials And program. the with formulation a can. with technology a its pleased to X to after BMS addition TECENTRIQ conducting and our finally, Shortly Phase kickoff patients. initiate X to
regulatory our our We in expanding horizon, just continuing half the build oncology development Perjeta/Herceptin turn ENHANZE pillar you've in XXXX of why dose on XXXX. for and billion can see for business the you key clinic. now X. clinical to heard, to our I'll that deliver and second royalty Slide the revenues regulatory have submissions forward platform momentum programs we the in ENHANZE in submissions As DARZALEX to the beginning approximately has With $X is potential conviction on combination XXXX. fixed the in look to partners'
temporarily high revenue hyaluronan, tumors is Our the PEGPHXX, oncology constrict targeted pillar of vasculature. or a that development our as around we pillar certain can second the potential tumor that accumulate degrades and therapy continue HA,
studying XXX PEGPHXX in with to tumors. a HA patients. in metastatic Ventana, pancreas study December a partner, global XXXX with gemcitabine our of with PEGPHXX enrollment completed evaluating combination Phase are first-line developed cancer with randomized, in We high tumors. with companion identify diagnostic X and patients double-blind, of HALO-XXX with approximately ABRAXANE patients We HALO-XXX high HA is
third months. As XX% minimal primary study power ratio XXX initiate have achieved and analysis with median a we survival, survival mature we will for and the single X.X events expect data. endpoint is process a quarter. observable the XXX HALO-XXX a well-powered database currently we We of with a the And for is lock X.XX overall in target reminder, overall of final OS to events plan approximately after hazard difference of that a achieve
As we expect a will that half result, available in second top the be of line XXXX. can results
Without cohort. completed study. in an recently our results we of cancer on tumor The exciting for the arm evaluation in MORPHEUS in Let's that, study from an update will Laurie? with Tecentriq results Xb Enrollment Halozyme-led to trial in evaluating types. our to I With XXXX. PEGPHXX doubt, in anticipate X will we cholangiocarcinoma HALO-XXX time combined oncology complete, PEGPHXX enrolled and in study detail. I'll the patients XX their other is Slide in expect we to call with results later look expansion greater pancreas study enrollment continue to Roche turn in in and available now cancer, this that XXXX. total, a be financial pillar. second-line Xb/X Phase the and gallbladder PEGPHXX is in year. And forward Phase to later over results discuss is later turn Laurie this our and the
